Reference health
Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Patients With Somatostatin Receptor–Expressing Neuroendocrine Tumors
29/29 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
4 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 29 checked references that resolve
resolves10.1200/JCO.2007.15.4377
One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States
resolves10.1038/sj.bjc.6690325
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin
resolves10.1007/s00259-011-1835-8
Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)
resolves10.1200/JCO.2009.22.8510
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
resolves10.1111/j.1572-0241.1998.066_c.x
Somatostatin-Receptor Scintigraphy in the Management of Gastroenteropancreatic Tumors
resolves10.1007/s11307-010-0374-1
68Ga-DOTA-NOC PET/CT Imaging of Neuroendocrine Tumors: Comparison with 111In-DTPA-Octreotide (OctreoScan®)
resolves10.1111/j.1749-6632.1994.tb17300.x
Radiotherapy with a Radiolabeled Somatostatin Analogue, [<sup>111</sup>In‐DTPA‐<scp>d</scp>‐Phe<sup>1</sup>]‐Octreotide
resolves10.1089/cbr.2007.0448
Safety and Efficacy of Radionuclide Therapy with High-Activity In-111 Pentetreotide in Patients with Progressive Neuroendocrine Tumors
resolves10.7150/thno.3739
Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 Pentetreotide
resolves10.1093/annonc/10.suppl_2.S23
Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy
resolves10.1023/A:1011160913619
The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study
resolves10.1200/JCO.2007.15.2553
Treatment With the Radiolabeled Somatostatin Analog [
<sup>177</sup>
Lu-DOTA
<sup>0</sup>
,Tyr
<sup>3</sup>
]Octreotate: Toxicity, Efficacy, and Survival
resolves10.1016/0021-9681(61)90060-1
The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent
resolves10.1200/JCO.2004.10.016
Quality of Life in Patients With Gastroenteropancreatic Tumors Treated With [<sup>177</sup>Lu-DOTA<sup>0</sup>,Tyr<sup>3</sup>]octreotate
resolves10.2967/jnumed.111.087932
Quality of Life in 265 Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors Treated with [<sup>177</sup>Lu-DOTA<sup>0</sup>,Tyr<sup>3</sup>]Octreotate
resolves10.1007/s00259-010-1631-x
Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours
resolves10.1677/ERC-09-0078
Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
resolves10.1159/000335018
Treatment of Gastroenteropancreatic Neuroendocrine Tumors with Peptide Receptor Radionuclide Therapy
resolves10.1007/s002590100574
[177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients
resolves10.1053/snuc.2002.31769
Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies
resolves10.1530/ERC-10-0282
Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours
resolves10.1080/02841860701441848
Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours
resolves10.1007/s00259-002-1050-8
Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate
resolves10.1016/j.ecl.2010.12.003
Somatostatin Receptor-Targeted Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors
resolves10.1007/s12149-012-0578-3
Peptide receptor radionuclide therapy of Merkel cell carcinoma using 177lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: a potential novel treatment based on molecular pathology
The 4 references without a DOI — listed, not checked
no DOI — not checkedTumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC.
no DOI — not checkedLong-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy.
no DOI — not checkedAnalysis and interpretation of response rates for anticancer drugs.
no DOI — not checkedBiodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1097/mpa.0000000000000113"><img src="https://citestamp.com/citestamped/10.1097/mpa.0000000000000113/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1097/mpa.0000000000000113)